Adynovate Purple Book BLA 125566

BLA number
125566
Proprietary names
Adynovate
Proper names
Antihemophilic Factor (Recombinant), PEGylated
Applicant
Takeda Pharmaceuticals U.S.A., Inc.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)1000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2015-11-13
002AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)2000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2015-11-13
003AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)250IUFor InjectionIntravenousSingle-Dose VialRxLicensed2015-11-13
004AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2015-11-13
005AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)1500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-10-25
006AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)750IUFor InjectionIntravenousSingle-Dose VialRxLicensed2016-10-25
007AdynovateAntihemophilic Factor (Recombinant), PEGylated351(a)3000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2017-03-13

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-05-01U001Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U002Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U003Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U004Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U005Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U006Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U007Adynovate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2021-05-01U001Adynovate351(a)RxBaxalta US Inc.
2021-05-01U002Adynovate351(a)RxBaxalta US Inc.
2021-05-01U003Adynovate351(a)RxBaxalta US Inc.
2021-05-01U004Adynovate351(a)RxBaxalta US Inc.
2021-05-01U005Adynovate351(a)RxBaxalta US Inc.
2021-05-01U006Adynovate351(a)RxBaxalta US Inc.
2021-05-01U007Adynovate351(a)RxBaxalta US Inc.
2020-08-01R001Adynovate351(a)RxBaxalta US Inc.
2020-08-01R002Adynovate351(a)RxBaxalta US Inc.
2020-08-01R003Adynovate351(a)RxBaxalta US Inc.
2020-08-01R004Adynovate351(a)RxBaxalta US Inc.
2020-08-01R005Adynovate351(a)RxBaxalta US Inc.
2020-08-01R006Adynovate351(a)RxBaxalta US Inc.
2020-08-01R007Adynovate351(a)RxBaxalta US Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Adynovate351(a)RxLicensed2015-11-13
2020-08-01002Adynovate351(a)RxLicensed2015-11-13
2020-08-01003Adynovate351(a)RxLicensed2015-11-13
2020-08-01004Adynovate351(a)RxLicensed2015-11-13
2020-08-01005Adynovate351(a)RxLicensed2016-10-25
2020-08-01006Adynovate351(a)RxLicensed2016-10-25
2020-08-01007Adynovate351(a)RxLicensed2017-03-13